The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

“AI can help us to find patterns in data and, increasingly ... AI is increasingly being explored by most big pharmaceutical companies eager to advance their own programs and accelerate the pace of ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...

(THE CONVERSATION) The potential of using artificial intelligence in drug discovery and development has sparked both ... in the drug development process when provided with high-quality data and ...

The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA ...

In recent years, generative AI (GenAI) has become a prominent topic of discussion in life sciences. However, I often hear from my life science clients about the need for more clarity around its ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.